Citations

Clear

4799 citation(s) found for "Ro, Jennifer".

“CARING in Action”: A Knowledge Mobilization Project on Co-Creating Evidence-Based Communication Training in Chronic Pain Care for Healthcare Professionals
Taccardi, Doriana , Suárez, Nataly R. Espinoza , Shah, Swapnil, Daly-Cyr, Jennifer , LeBlanc, Annie , Ghasemlou, Nader , Cooper, Lynn , Bosma, Rachael, Roy, Rachel , Espinoza Suarez, Nataly R , Shah, Swapnil, Bosma, Rachael, Roy, Rachel

Mayo Clinic

Canadian Journal of Pain | August 6, 2026 | Volume: 10 | Issue: 1 | Pages: No page available

10.1080/24740527.2026.2696249 | PMID 42569207 Get It

Machine learning-derived clinical phenotypes of ascites in cirrhosis: A multi-center latent class analysis with external validation
Lai, Jennifer C., Liu, Taryn, Gomez, Miguel E., Simonetto, Douglas A., LEE, SEAN, Lee, Brian P., Allegretti, Andrew S. , Mazumder, Nikhilesh R., Patidar, Kavish R., Verna, Elizabeth C. , Cullaro, Giuseppe , Lai, Jennifer C. , Simonetto, Douglas A. , Lee, Brian P. , Mazumder, Nikhilesh R. , Patidar, Kavish R.

Mayo Clinic

Liver Transplantation | August 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/lvt.0000000000000942 | PMID 42560069 Get It

Ascites development in cirrhosis reduces 5-year survival from 80% to 30%, yet substantial heterogeneity exists among patients with comparable ascites severity. This multicenter retrospective cohort study included adult liver transplant candidates with ascites at 4 United States centers (2015–2024). Latent class analysis was performed using 7 clinical variables: ascites grade, bilirubin, albumin, platelet count, estimated glomerular filtration rate, systolic blood pressure, and portal vein thrombosis. The derivation cohort (n=625) from the University of California San Francisco and Columbia University was randomly split 80/20 for model development and internal validation. External validation was performed at the University of Southern California (n=59) and Mayo Clinic (n=93). Primary outcomes were acute kidney injury (AKI) and waitlist mortality over 365 days. Three phenotypes emerged: “CKD-Metabolic” (30.4%, lowest eGFR 76.5 mL/min/1.73 m 2 ), “Vasodilatory-Synthetic Dysfunction” (38.9%, highest bilirubin 7.03 mg/dL, lowest blood pressure 117.5 mmHg), and “PVT-Intermediate” (30.7%, severe thrombocytopenia 68.1×10 3 /μL, 24.0% PVT). In validation cohorts (n=305), phenotypes demonstrated robust classification (mean posterior probability 0.823–0.855). Vasodilatory-Synthetic Dysfunction showed increased AKI risk versus CKD-Metabolic in derivation (MELD 3.0-adjusted HR 2.95, 95% CI 2.07–4.22, p <0.001) and validation cohorts (HR 3.39, 95% CI 1.93–5.94, p <0.001). Competing risk analysis revealed no mortality differences, but Vasodilatory-Synthetic Dysfunction was associated with higher transplantation rates (validation: HR 1.63, 95% CI 1.19–2.22, p =0.002). Three reproducible clinical phenotypes of ascites were identified with distinct risk profiles. The Vasodilatory-Synthetic Dysfunction phenotype was associated with a 3-fold increase in the risk of AKI that persisted after adjustment for MELD 3.0. No differences in waitlist mortality were observed, likely reflecting effective MELD-based transplant allocation that preferentially removes the highest-acuity patients from the waitlist.
Engraftment across major ABO blood group and rhesus E antigen incompatibility in the presence of persistent anti-E antibodies and late serologic findings coinciding with disease relapse
Fathima, Saubia, Sullivan, Luz Y. , Schieber, Jennifer, Matin, Aasiya, Gandhi, Manish J, Fathima, Saubia , Schieber, Jennifer, Matin, Aasiya , Gandhi, Manish J.

Mayo Clinic

BMJ Case Reports | August 6, 2026 | Volume: 19 | Issue: 8 | Pages: e275699

10.1136/bcr-2026-275699 | PMID 42562449 Get It

ABO incompatibility is frequent in haematopoietic stem cell transplantation (HSCT), yet the clinical impact of non-ABO red blood cell (RBC) alloimmunisation remains less defined. We describe the clinical course of a man in his 50s with chronic eosinophilic leukaemia who underwent a mismatched unrelated donor (MMUD) HSCT. Despite a major ABO mismatch and high-titre pre-existing anti-E antibodies against an E-antigen positive donor, the patient achieved successful trilineage engraftment without haemolysis. Six months after the transplant, he developed severe pancytopenia and a positive direct antiglobulin test (DAT) with anti-E elution. These serologic findings coincided with disease relapse rather than isolated immune-mediated haemolysis. This case illustrates that successful engraftment is possible across RhE-incompatibility and underscores the need to interpret late serologic abnormalities within the broader context of graft function and disease status.
Addition of High-Dose Vitamin D 3 to Standard Treatment in Patients With Metastatic Colorectal Cancer
Ng, Kimmie, Zemla, Tyler, Jackson, Nadine, Kalyan, Aparna, Devoe, Craig, Shusterman, Michael , Vijayvergia, Namrata , Wu, Christina S., Cohen, Stacey A., Pulsipher, Sidney, Shergill, Ardaman, Watson, Yasmeem, Kleiber, Barbara , Lee, Myounghee, Kohn, Christine G. , Zuckerman, Dan, Hollis, Bruce W., O’Reilly, Eileen M., Meyerhardt, Jeffrey A., Pulsipher, Sydney , Ng, Kimmie , Ou, Fang‐Shu , Zemla, Tyler , Devoe, Craig , Cohen, Stacey A. , Thalappillil, Jennifer S. , Schwartz, Lawrence H. , Zuckerman, Dan, Hollis, Bruce W. , O’Reilly, Eileen M. , Meyerhardt, Jeffrey A.

Mayo Clinic

JAMA | August 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jama.2026.9350 | PMID 42545685 Get It

Importance In a phase 2 randomized clinical trial, high-dose vitamin D 3 added to standard treatment improved progression-free survival (PFS) compared with standard-dose vitamin D 3 in patients with metastatic colorectal cancer (mCRC). Objective To determine if high-dose vitamin D 3 added to standard chemotherapy improves outcomes in patients with previously untreated mCRC. Design, Setting, and Participants Double-blind phase 3 randomized clinical trial enrolling 455 patients with previously untreated mCRC, conducted in the US through the National Clinical Trials Network from October 2019 to December 2022 (database freeze: July 15, 2024). Interventions mFOLFOX6 (modified FOLFOX6 [5-fluorouracil, leucovorin, oxaliplatin]) or FOLFIRI (5-fluorouracil, leucovorin, irinotecan) plus bevacizumab every 2 weeks with either high-dose vitamin D 3 (8000 IU daily × 14 days as loading dose followed by 4000 IU daily) or standard-dose vitamin D 3 (400 IU daily) until disease progression, intolerable toxicity, or withdrawal of consent. Main Outcomes and Measures The primary end point was PFS assessed by the unstratified log-rank test. Secondary end points included objective response rate, overall survival, and toxicity. Prespecified subgroup analyses of PFS were performed according to known prognostic factors. Results Among 455 randomized patients (median age, 59 years; 181 [40%] female) with median follow-up 20 months, the median PFS for high-dose vitamin D 3 (n = 228) was 11.8 months (95% CI, 10.3-13.3) vs 10.3 months (95% CI, 9.4-12.2) for standard-dose vitamin D 3 (n = 227) (1-sided log-rank P = .25). There were no significant differences in objective response rate between high-dose and standard-dose vitamin D 3 (51% [95% CI, 44%-58%] vs 44% [95% CI, 37%-50%], respectively; P = .12), or in overall survival (median, 25.6 vs 27.0 months; 1-sided log-rank P = .66). There were no clinically meaningful differences in the most common grade 3 or greater adverse events between the high- and standard-dose groups, including neutropenia (n = 67 [32%] vs n = 62 [30%]) and hypertension (n = 42 [20%] vs n = 49 [23%]) or in incidence of vitamin D–associated toxicities. Conclusions and Relevance Among patients with previously untreated mCRC, addition of high-dose vitamin D 3 , vs standard-dose vitamin D 3 , to standard chemotherapy plus bevacizumab did not improve PFS. Trial Registration ClinicalTrials.gov Identifier: NCT04094688
Breast cancer ovarian metastases show increased activity of GPCR pathways
Savariau, Laura , Qin, Ye, Shah, Osama Shiraz , Basudan, Ahmed , Merkel, Chris , Sisoudiya, Saumya D. , Sivakumar, Smruthy , Sokol, Ethan , McGinn, Olivia , Li, Zheqi , Liu, Tiantong , Tasdemir, Nilgun , Tallapaneni, Pooja , Oesterreich, Steffi , Shah, Osama , Basudan, Ahmed M , Coffman, Lan , Elishaev, Esther , Lucas, Peter C , Lee, Adrian V , Oesterreich, Steffi , Li, Zheqi , Savariau, Laura , Elishaev, Esther , Atkinson, Jennifer M. , Lucas, Peter C. , Lee, Adrian V.

Mayo Clinic

No container title available | August 1, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.07.30.741805 | PMID 42619866 Get It

Abstract Treatment resistance and metastases occur in 10–20% of patients with invasive lobular carcinoma (ILC), the most common special histological subtype of breast cancer. ILC metastasizes to the ovary more frequently than no special type (NST) tumors, also known as invasive ductal carcinoma (IDC). To characterize the genomic landscape of breast cancer ovarian metastases, we analyzed 15,613 local breast cancers, 22,010 non-ovarian metastases, and 246 ovarian metastases sequenced using FoundationOne®CDx or FoundationOne® assays. Ovarian metastases had enriched CDH1 , PIK3CA , and TBX3 mutations and depleted TP53 and MYC alterations relative to local breast cancers, with additional depletion of ESR1 mutations compared to non-ovarian metastases. CDH1 mutations were less frequent in ovarian metastases (47%) than local ILC (81.3%), with reduced 16q loss (64% vs 84%), indicating that ovarian metastases also arise from non-ILC tumors. We extended these findings to a UPMC cohort of 27 ovarian metastases (13 ILC, 8 IDC, 6 mixed ductal-lobular carcinoma) with patient-matched primary tumors in most cases. In both cohorts, patients with ovarian metastases were significantly younger than those with other metastatic sites. In the UPMC cohort, the most frequent mutations were in PIK3CA , CDH1 , KMT2C , FOXA1 , and RUNX1 . Transcriptomic analysis identified upregulated G protein-coupled receptor (GPCR) pathways, including metabotropic glutamate receptor signaling. Functional studies showed that calcium-sensing receptor (CaSR), a GPCR overexpressed in ovarian metastases, drives MEK/ERK-dependent migration and F-actin reorganization in ILC cell lines, enhanced by estrogen and blocked by calcilytic, MEK, or anti- estrogen treatment. Our findings inform future therapeutic targeting of ovarian metastasis.
Approach to Peripheral Neuropathies Leading to Hospital Admission
Hass, Reece M. , Santilli, Ashley R. , Martinez‐Thompson, Jennifer M. , Pinto, Marcus Vinícius , Pinto, Marcus V , Hass, Reece M. , Santilli, Ashley R

Mayo Clinic

Neurology Education | July 31, 2026 | Volume: 5 | Issue: 3 | Pages: No page available

10.1212/ne9.0000000000200341 | PMID 42549412 Get It

Justice-Oriented Evaluation of Antiracist Medical Education: A Critical Scoping Review of Antiracism Educational Intervention Methodologies in Medical Education
Randall, Jennifer , Crespo-Cruz, Eduardo, Vime-Olive, Maya, Usher, Ellen L.

Mayo Clinic

Teaching and Learning in Medicine | July 31, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-15

10.1080/10401334.2026.2707290 | PMID 42535763 Get It

DNR Status and Hospital Mortality Measures Postmyocardial Infarction: Differentiating Preventable From Unpreventable Deaths in CMS Data
Danks, Annette M., Chirilă, Răzvan M. , Franco, Pablo Moreno , Ray, Jordan , Dowdy, Sean C. , Cowart, Jennifer B. , Pollock, Benjamin D , Danks, Annette M , Chirila, Razvan M , Moreno Franco, Pablo , Ray, Jordan C , Dowdy, Sean C , Cowart, Jennifer B , Pollock, Benjamin D.

Mayo Clinic

Circulation: Population Health and Outcomes | July 30, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1161/circoutcomes.125.013117 | PMID 42529828 Get It

BACKGROUND: Publicly reported 30-day acute myocardial infarction (AMI) mortality rates are widely used to benchmark hospital performance. However, these measures may lack validity when they include deaths among patients with do-not-resuscitate (DNR) orders or those receiving palliative care—groups for whom mortality may be expected and goal-concordant. METHODS: We analyzed the national 100% Medicare Inpatient Standard Analytic File and Medicare Beneficiary Summary file to assess 30-day AMI mortality rates stratified by DNR status (absent, present-on-admission, and postadmission) and palliative care involvement. We then conducted a retrospective chart review of all 30-day AMI mortalities at a single academic medical center (2019–2025), applying Global Registry of Acute Coronary Events and a Palliative Performance Scale scores to identify unpreventable deaths, which we defined as a Global Registry of Acute Coronary Events >190.5 or Palliative Performance Scale ≤40%. Global Registry of Acute Coronary Events is a risk-stratification tool using clinical and laboratory variables whereas the Palliative Performance Scale is a bedside functional status and palliative care assessment quantifying patient’s self-care ability. RESULTS: Across n=467 259 total AMI encounters, mean (SD) age was 75.1 (10.5), and the population was 44% female. Thirty-day mortality was 10.4% (39 112/376 062) among patients without DNRs, 43.1% (26 181/60 719) in those with present-on-admission DNR, and 72.1% (21 984/30 478) in those with postadmission DNR. Among 9.2% (43 090/467 259) of encounters with palliative care, there was a 76.9% mortality rate (33 151/43 090). Hazard ratios for mortality were 5.25 (95% CI, 5.17–5.33) for present-on-admission DNR and 10.73 (95% CI, 10.55–10.91) for postadmission DNR as compared with encounters without DNRs. Among n=24 AMI mortalities at our institution, 71% (17/24) had DNRs, and 33% (8/24) met the unpreventable death criteria. CONCLUSIONS: The validity of 30-day AMI mortality metrics may be undermined by their inclusion of high-acuity, end-of-life patients, which may disincentivize hospitals from delivering appropriate, patient-centered care. Removal of DNR or palliative cases from performance measures should be explored to better identify opportunities for reducing preventable deaths.
Factors That Influence Genetic Counselors' Professional Identity—A Qualitative Study
Schwartz, Lisa , Stenberg, Kaye , Casey, Andrea , Fitzpatrick, Jennifer , Mackall, Mia S. , Arjunan, Aishwarya , Witherington, Sarah , Kalia, Isha , Mills, Rachel , Goodenberger, McKinsey , Arjunan, Aishwarya , Witherington, Sarah , Kalia, Isha , Mills, Rachel , Casey, Andrea , Fitzpatrick, Jennifer , Goodenberger, McKinsey L.

Mayo Clinic

Journal of Genetic Counseling | July 30, 2026 | Volume: 35 | Issue: 4 | Pages: No page available

10.1002/jgc4.70260 | PMID 42528291 Get It

ABSTRACT Genetic counselors describe their professional identity as who they are (personal characteristics and attributes), what they do (actions and skills), and what they possess (training and knowledge). A shared multidimensional perspective highlights the transferability of their skills across diverse roles and settings. This qualitative study aimed to identify factors that influence genetic counselors' perceptions and formation of their professional identities. Using Social Identity Theory as a theoretical framework, semi‐structured recorded interviews were conducted with 50 genetic counselors who were purposefully sampled to ensure diversity of personal demographics (gender, race/ethnicity, sexual orientation, disability, and caregiver status), as well as years, settings, and roles in genetic counseling practice. Transcripts were coded and subjected to codebook thematic analysis using NVivo. Professional identity was influenced by internal validation (sense of purpose in work, pride, and confidence), external validation (from other colleagues, work system, degree of autonomy, and patients), one's personal identities (demographics, life experiences, and persona), and connections with others (professional network, peer support, role models, and giving back). Alignment and misalignment of these factors and the perceived collective identity of the profession impacted genetic counselors' sense of belonging to the profession both positively and negatively, respectively. Continued efforts to diversify the profession, as well as expanded opportunities for genetic counselors to work in new settings and roles, require critical reflection and discussion about the collective identity of the genetic counseling profession. The findings of this study can inform the recruitment, training, credentialing, continuing education, and retention of genetic counselors to ensure that genetic counselors, regardless of their personal identities or their work roles or settings, develop and maintain a sense of belonging and commitment to the profession and its values. In turn, the support of professional identity formation can positively impact genetic counselors' job satisfaction, competency, and delivery of healthcare to their patients and the populations they serve.
Combination of Radiation Therapy and Irreversible Electroporation for Intermediate-Risk Prostate Cancer (RTIRE): A Phase 1 Trial
Mcclure, Timothy D. , Ballman, Karla V. , Diven, Marshall, Osborne, Joseph R. , O’Dwyer, Elisabeth , Piscopo, Jennifer, Khani, Francesca , Marciscano, Ariel, Awamlh, Bashir Al Hussein Al , Wang, Shu , Ballman, Karla , Osborne, Joseph R , Al Hussein Al Awamlh, Bashir , Barbieri, Christopher , Nagar, Himanshu , Diven, Marshall A., Marciscano, Ariel E.

Mayo Clinic

Radiology | July 28, 2026 | Volume: 320 | Issue: 1 | Pages: No page available

10.1148/radiol.250848 | PMID 42517770 Get It

Treatment of participants with intermediate-risk prostate cancer with focal irreversible electroporation and radiation therapy was technically feasible and showed acceptable patient-reported outcomes and no severe adverse events over 1 year.